Deal Furthers LENSAR Laser System Lead in Computer Guidance for Refractive Cataract Surgery Market
ORLANDO, Fla., and SANTA BARBARA, Calif., April 22, 2014 – LENSAR Inc. and TrueVision 3D Surgical, today announced a global co-development and distribution agreement that integrates TrueVision’s TrueGuide® system into the LENSAR Laser System’s advanced technology suite.
The LENSAR Laser System is an intelligent femtosecond cataract surgery laser that offers superior imaging, measurement and 3-D modeling technology. Cataract surgeons worldwide have responded to the ergonomic efficiencies and imaging innovation of the LENSAR Laser System, reporting that it has redefined safety and enabled them to treat even the most difficult cataract cases and helped to reduce the total phaco time and energy that is typically required.
“Surgeons using the LENSAR Laser system with our proprietary Augmented Reality™ image and guidance will now have the added benefit of TrueVision’s overlay and nomogram which will be incorporated seamlessly into LENSAR’s efficient surgical suite,” said Nick Curtis, LENSAR CEO. “This deal is a continuation of our commitment to drive innovation and advance refractive cataract surgery.”
The LENSAR Laser System with TrueGuide® will premiere at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium and Congress in Boston, April 24-29, 2014.
Jonathan Solomon, M.D., said, “We have embraced these advanced technologies that enable the use of preoperative imaging and planning in the operative theatre. We use the LENSAR Laser System for astigmatic incision creation and intelligent cataract fragmentation and then TrueVision’s computer guidance templates to place and position lens implants. Each component offers unique surgical advantages that benefit both surgeons and patients to improve the key steps of cataract surgery.”
LENSAR’s Augmented Reality imaging technology rotates around the eye and takes scanning images at multiple angles to locate and identify the relevant ocular surfaces, measuring them and capturing exact biometric data. This information is then used to create a 3-D model of the anterior anatomy to help guide customized treatment and precise laser placement of each laser pulse. It is the LENSAR Laser System’s Augmented Reality imaging that provides surgeons with unsurpassed clarity and accuracy, giving them the information they need to plan and perform an individualized procedure on each patient.
“A partnership to optimize this suite of technologies is the next logical step in the evolution of refractive cataract surgery. Streamlining and automating the processes from preoperative planning to intraoperative guidance will enhance femtosecond laser treatments,” said Robert Weinstock, MD. “We expect that this will translate into more accurate results for our patients and improved customization of the individual surgical plan. It is exciting to see these incredible technologies come together to help us deliver better care to our patients.”
Ophthalmic surgeons will have a chance to learn about the latest advancements with this suite of equipment and speak with experienced users by visiting LENSAR booth #1321 during the 2014 American Society of Cataract and Refractive Surgery Symposium & Congress in Boston, April 25-29.
About TrueVision, Inc.
TrueVision® 3D Surgical is a world leader in digital 3D visualization and guidance for microsurgery. Santa Barbara, California-based TrueVision® has developed and patented an intelligent, real-time, 3D surgical visualization and computer-guided software platform. The company is focused on developing a suite of 3D guidance applications for microsurgery to improve surgical efficiencies and patient outcomes. The system is in use at hundreds of leading hospitals and institutions around the world. www.truevisionsys.com
About LENSAR, Inc.
LENSAR, Inc. is a leader in the development and commercialization of an intelligent femtosecond cataract laser and superior imaging, measurement and 3D modeling technology. The LENSAR Laser System has been cleared by the FDA for anterior capsulotomy, lens fragmentation and corneal and arcuate incisions. For other indications, it is an investigational device limited by U.S. law to investigational use only. For more information, please visit www.lensar.com.